 activ specif immunotherapi patient melanoma clinic trial mous monoclon antibodi syngen anti-high-molecular-weight-melanoma-associ antigen monoclon antibodi erratum clin invest feb clinic trial mous monoclon antibodi mab intern imag human high-molecular-weight-melanoma-associ antigen hmw-maa subcutan rout adjuv patient stage IV malign melanoma day addit inject anti-antiidiotyp antibodi titer first phase trial patient initi dose mg inject mg inject toxic allerg reaction develop anti-mous Ig antibodi minor respons patient second clinic trial mab patient dose mg inject dose initi studi effect anti-antiidiotyp antibodi patient inevalu patient averag durat treatment wk trial toxic allerg reaction immun patient level anti-mous Ig antibodi develop antibodi bind antiidiotyp mab anti-hmw-maa mab patient level anti-hmw-maa antibodi patient complet remiss disappear multipl abdomin lymph node durat wk minor respons patient result mous antiidiotyp mab intern imag hmw-maa use reagent activ specif immunotherapi patient melanoma